{"id":"W2980937306","doi":"10.1038/s41375-019-0602-x","title":"Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study","year":2019,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":463,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"National Cancer Institute; TG Therapeutics; Astellas Pharma; BeiGene; Gilead Sciences; GlaxoSmithKline; Pharmacyclics; Genentech; Sunesis; Teva Pharmaceutical Industries; Celgene; AstraZeneca; Bristol-Myers Squibb","keywords":"Ibrutinib; Chlorambucil; Internal medicine; Neutropenia; Medicine; Chronic lymphocytic leukemia; IGHV@; Adverse effect; Hematology; Oncology; Gastroenterology; Leukemia; Chemotherapy; Cyclophosphamide","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004857673,0.0005813834,0.001803794,0.0004707979,0.0006384694,0.001609441,0.0006290513,0.001554435,0.001337224],"category_scores_gemma":[0.003196299,0.0003130238,0.002920721,0.0006381545,0.0004224122,0.001131834,0.0005777659,0.002499414,0.0004576696],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001083342,"about_ca_system_score_gemma":0.0008771886,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001334463,"about_ca_topic_score_gemma":0.002273757,"domain_scores_codex":[0.9989323,0.0003510555,0.00009544702,0.000162072,0.0002007857,0.0002583147],"domain_scores_gemma":[0.9961097,0.0006787207,0.001374022,0.000303306,0.000379777,0.001154577],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3671989,0.008195967,0.4638736,0.0008457054,0.009996315,0.0007443396,0.0005561061,0.003604116,0.0070372,0.0001861504,0.00507258,0.132689],"study_design_scores_gemma":[0.03348591,0.08509018,0.8662652,0.0002146805,0.006152929,0.0006650213,0.0001859802,0.001853184,0.001596962,0.0003473334,0.00402241,0.0001201903],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9885082,0.007259744,0.0002735038,0.0003525385,0.00005679307,0.0001517069,0.00217558,0.00003210226,0.0011898],"genre_scores_gemma":[0.993865,0.0009603171,0.0001256847,0.0005974881,0.00008384646,0.0001144868,0.003700422,0.000007775854,0.0005450536],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004857673,"threshold_uncertainty_score":0.02569014,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0243989745233313,"score_gpt":0.3168264164823156,"score_spread":0.2924274419589843,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}